DNA Stock Chart & Stats
$170.00
$0.00(0.00%)
At close: 4:00 PM EDT
$170.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$110.00 - $289.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$8.39B
Enterprise Value$395.48
Total Cash (Recent Filing)$373.46M
Total Debt (Recent Filing)$410.70M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Aug 06, 2026EPS Estimate
-15.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding53,361,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$209.21Price Target Upside23.06% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~81% gross margins indicate the core platform generates high incremental profitability on incremental revenue. This structural margin advantage (automation, software, IP) provides meaningful operating leverage over time, enabling faster path to profitability as sales scale and fixed costs are absorbed.
Scaling Autonomous Lab (Nebula)Material expansion of Nebula racks and protocol usage demonstrates platform scale, customer engagement, and higher technical barriers to entry. Durable benefits include stronger product-market fit, deeper device integrations, and potential network effects that can drive recurring service demand if commercialization continues to progress.
Stronger Cash Runway And Cost ReductionsA $373M cash position and zero bank debt combined with committed burn guidance and recent R&D/G&A cuts provide multi-quarter runway. This financial cushion supports continued investment in Nebula, AI integration and channel builds while management executes structural cost reductions to extend optionality.
Bears Say
Sharp Revenue ContractionSustained and steep revenue decline weakens unit economics and delays realization of platform operating leverage. For a capital‑intensive platform, falling top line increases execution risk: fixed operating costs and scaling Nebula depend on durable revenue growth that has not yet materialized.
High Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow implies ongoing reliance on external financing to fund operations and capital needs. Even with recent burn improvement, the structural cash deficit constrains strategic flexibility and raises funding risk if revenue recovery or milestone monetization is delayed.
Rising Leverage And Negative ReturnsIncreasing leverage alongside materially negative returns on equity points to deteriorating financial flexibility. In a loss-making phase, higher debt increases downside risk, limits capacity for opportunistic investment, and exacerbates sensitivity to funding markets or slower-than-expected commercialization.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $110.00 and its highest was $289.00 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is $8.39B.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 9 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on May 07, 2026. The company reported -$24.269 earnings per share for the quarter, missing the consensus estimate of -$21.144 by -$3.125.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -15.63.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 53,361,140 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$24.269 in its last earnings report, missing expectations of -$21.144. Following the earnings report the stock price went down -13.826%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Currently, no hedge funds are holding shares in MX:DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$209.21 (23.06% Upside)
$209.21 (23.06% Upside)
Blogger Sentiment
Neutral
MX:DNA Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: meaningful operational and strategic progress in autonomous labs (Nebula), AI-driven experiments, partnerships and a strong cash position, alongside significant near-term financial challenges including a sharp revenue decline, ongoing losses, negative adjusted EBITDA and cash costs from excess leases and one-time payments. Execution and commercialization of Nebula, cloud lab and channel partnerships will determine whether the recent technical and commercial wins translate into durable revenue growth.View all MX:DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$209.21
▲(23.06% Upside)